SMN1 and spinal muscular atrophy, type II: The assay was evaluated by characterization of the SMN baseline expression level in blood samples taken from eight individuals - two patients affected by SMA type II, two patients affected by SMA type III, one asymptomatic individual, one SMA carrier and two healthy controls (Table 1).